NASDAQ: BMRN

BioMarin Pharmaceutical (BMRN) Stock Analysis & Forecast

Nov 13 close

$57.23+0.53 (+0.9%)

Gekko Brief

AI summaryNov 9 close

BioMarin's third-quarter 2026 revenue rose to $1,024.6 million, up from $776.1 million a year earlier, driven by sales of Galafold and Pombiliti + Opfolda following the Amicus acquisition, though the quarterly net loss widened. H.C. Wainwright reiterated a Neutral rating with a $60.00 price target, citing caution on Voxzogo's U.S. retention ahead of potential oral competition and before hypochondroplasia revenue contributes. The company also announced management will present at three November investor conferences, and traders acquired an unusually large volume of call options on 4 November.

BMRN closed at $57.18, up 2.1%, sitting between its 50-day average of $59.54 and 200-day average of $58.45. The GekkoIndex reads 58.7, in the Neutral zone, down 0.5 over five sessions. Shares trade 12.6% below Gekko Fair Value of $65.39, with a 52-week range of $49.26 to $70.98 and a three-month return of -17.8%.

The next earnings report is scheduled for 22 February 2027, 99 days away, placing it outside a typical 20-trading-day holding window. Over the last 30 days, one unusual options signal was recorded, with call premium of $339,327 against no put premium. One billionaire holder is noted, with no trailblazer holders. Seasonally, the next 20 trading days have averaged +8.5% over five years, rising in 5 of them. Analyst consensus across 22 firms includes 16 buy and 6 hold ratings, with a consensus target of $91.04.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

BioMarin Pharmaceutical price vs fair value

$65.36$57.23Nov ’25May ’26Nov ’26
Close $57.23200-day averageGekko Fair Value $65.36

BioMarin Pharmaceutical quick facts

Market cap
$11.09B
P/E ratio
—
Forward P/E
8.7
EPS, TTM
−$0.10
Revenue, TTM
$3.66B
Profit margin
-0.5%
Dividend yield
—
Beta
0.23
Volume
1.47M avg 2.43M
1-year return
+3.5%
Typical daily move
±3.4%
Typical 20-day move
±5.3%
50-day average
$58.86
200-day average
$58.46
Next earnings
Feb 22 after close
Shares outstanding
193.7M
52-week range
$49.26$70.98

BioMarin Pharmaceutical swing-trade checklist

BioMarin Pharmaceutical scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive2 mixed0 headwinds

  • Trendmixed

    Averages disagree

    Close $57.23 sits between the 50-day ($58.86) and 200-day ($58.46) averages, or the averages disagree.

    See the chart
  • GekkoIndexmixed

    57.6, Neutral

    Reading 57.6 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuesupportive

    12.4% below

    Price is 12.4% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 30 days: 1 unusual options signal.

    See smart money
  • Earnings risksupportive

    Reports in 99 days

    Next report Feb 22, 2027, 99 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +7.7% on average

    From this point in the calendar, the next 20 trading days averaged +7.7% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

BioMarin Pharmaceutical stock chart and price history

BioMarin Pharmaceutical closed at $57.23 on Nov 13, 2026, +3.5% over the past year, inside a 52-week range of $49.26 to $70.98.

Close50-day average200-day averageVolume
BioMarin Pharmaceutical share price, past year, with 50-day and 200-day moving averages and volume$50$55$60$65$70DecJan 2026FebMarAprMayJunJulAugSepOctNov57.23

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+2.1%
3 months
−14.1%
6 months
+10.5%
1 year
+3.5%
The full BMRN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BMRN in Gekko

Follow BioMarin Pharmaceutical through every session

Put BMRN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track BMRN in GekkoFree for 7 days. No credit card required.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical develops and sells medicines for people with rare, often life-threatening genetic and metabolic disorders. Its marketed products include enzyme replacement therapies such as Vimizim, Naglazyme, Brineura and Aldurazyme, along with Kuvan and Palynziq for phenylketonuria and Voxzogo for achondroplasia. The company is best known for this concentrated focus on treatments for small, clearly defined patient populations rather than broader disease categories.

Alongside its approved therapies, BioMarin runs a pipeline of experimental treatments, including a gene therapy for severe hemophilia A now in Phase III trials and earlier-stage gene therapy programs aimed at phenylketonuria and primary hyperoxaluria. It sells through specialty pharmacies, hospitals, government health agencies, and distributors and wholesalers, reaching patients and providers in the United States, Europe, Latin America and other regions. The company also works with outside partners, including Sarepta Therapeutics, Ares Trading, Catalyst Pharmaceutical Partners and Asubio Pharma, on licensing and collaborative projects.

BioMarin was founded in 1996 and is headquartered in San Rafael, California. Its shares are listed on the NASDAQ under the ticker BMRN.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
biomarin.com

BioMarin Pharmaceutical GekkoIndex: the smart money zone

BioMarin Pharmaceutical’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 57.6, in the Neutral zone, down 3.5 points over five sessions.

010057.6Neutral

Down 3.5 points over five sessions, from the Accumulation zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying63+0.8%+1.9%+2.2%+1.1%
Accumulation269−0.2%−0.7%−0.6%+0.3%
Neutral (current zone)349−0.4%−0.7%−1.7%−4.3%
Distribution18−1.9%−3.1%−6.2%−11.0%
Selling3Too few readings yet

Average BMRN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the BMRN price, zone by zone.Track BMRN in Gekko

Is BioMarin Pharmaceutical stock overvalued? Gekko Fair Value

BioMarin Pharmaceutical trades 12.4% below Gekko Fair Value of $65.36, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what BioMarin Pharmaceutical shares are worth, recalculated every trading day.

$65.36

Gekko Fair Value, Nov 13, 2026

12.4% Undervalued

At the end of Sep 2026 the price was 13.1% below the estimate.

Gekko Fair ValueShare price, month end
$65$57Sep 2026OctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open BMRN in Gekko

BioMarin Pharmaceutical insider and Congress trading

No open-market insider purchases were filed for BioMarin Pharmaceutical, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for BMRN in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every BMRN insider filing, plotted on the chart in Gekko.Open BMRN in Gekko

Congress trades last 90 days

No trades in BMRN were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for BMRN, plotted on the chart in Gekko.Open BMRN in Gekko

Buybacks

BioMarin Pharmaceutical has been buying back its own shares.

Bought back, quarter ended Sep 30, 2026
$3.83M
As a share of market cap
0.03%
Trailing four quarters
$98.97M

From company filings.

Unusual options activity last 30 days

1signal, 100% of the flagged premium in calls.

Latest: Bullish flow on Oct 21, $339K in unusual premium.

Hedge funds and billionaires quarter ended Jun 30

1of the funds Gekko tracks holds BMRN.

1added0opened0trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

BioMarin Pharmaceutical earnings: next date and track record

BioMarin Pharmaceutical reports on Feb 22, 2027, after the close (99 days away), and beat the EPS estimate in 6 of its last 8 reports.

6 of 8reports beat the EPS estimate
±4%average move across the report
3 of 8reports followed by a gain

Share-price move across each report

−4.9%Oct ’24+6.0%Feb ’25−2.6%May ’25+6.5%Aug ’25−1.8%Oct ’25−2.3%Feb ’26−1.5%May ’26+6.5%Aug ’26

Last earnings call, Aug 6, 2026 AI summary

What they said
BioMarin delivered Q2 2026 revenue of nearly $1 billion, representing 20% year-over-year growth. The Amicus acquisition closed successfully, adding Galafold (peak revenue target $1.4B) and Pombility/Opfolda ($1.2B peak revenue), with $220M annual cost synergies expected by 2028. Voxzogo showed double-digit growth in US and international markets, with full-year guidance raised and an sNDA submitted for hypochondroplasia indication.
Guidance
Management raised Voxzogo full-year guidance, targeting $1B+ in revenue. Combined Amicus assets project $2.6B peak revenue potential through mid-2030s. H2 2026 expected stronger with full Galafold and Pombility/Opfolda contributions driving EPS accretion and margin expansion.
ReportedEPSSurpriseRevenueSurpriseMove
Aug 6, 2026$1.20
est $0.95
+26.7%$989.7M
est $932.0M
+6.2%+6.5%
May 4, 2026$0.76
est $0.91
−16.5%$766.0M
est $752.5M
+1.8%−1.5%
Feb 23, 2026$0.46
est $0.81
−43.5%$874.6M
est $833.7M
+4.9%−2.3%
Oct 27, 2025$0.12
est −$0.15
+180.0%$776.1M
est $823.5M
−5.7%−1.8%
Aug 4, 2025$1.44
est $0.86
+67.2%$825.4M
est $761.9M
+8.3%+6.5%
May 1, 2025$1.13
est $0.95
+18.9%$745.1M
est $738.7M
+0.9%−2.6%
Feb 19, 2025$0.92
est $0.74
+24.6%$747.0M
est $712.3M
+4.9%+6.0%
Oct 29, 2024$0.55
est $0.52
+5.8%$745.7M
est $712.3M
+4.7%−4.9%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

BioMarin Pharmaceutical stock forecast and analyst price targets

Analysts’ average 12-month price target for BioMarin Pharmaceutical is $90.78, +58.6% from the last close, from 23 firms rating the stock in the last 90 days.

$90.78consensus 12-month target, +58.6% from the last close
Low $60High $120
Buy17
Hold6
Sell0

Each firm’s latest rating in the last 90 days: 23 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 13Morgan StanleyBuy, reiterated$103+80.0%
Nov 13Evercore ISIBuy, maintained$120+109.7%
Nov 13Morgan StanleyBuy, maintained$103+80.0%
Nov 4H.C. WainwrightHold, reiterated$60+4.8%
Nov 4BarclaysBuy, maintained$114+99.2%
−1.7%average 20-day move after past Neutral readings
+7.7%average move over the next 20 trading days in the last 5 years
±3.4%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

BioMarin Pharmaceutical seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, BioMarin Pharmaceutical averaged +7.7% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

+1.0%2021+26.9%2022+16.1%2023+0.6%2024−4.8%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+2.5%3 of 5
Next 10 trading days+4.9%4 of 5
Next 15 trading days+6.7%3 of 5
Next 20 trading days+7.7%3 of 5
Next 30 trading days+10.5%5 of 5

For scale, BMRN’s typical 20-trading-day move in either direction is about 5.3%.

BioMarin Pharmaceutical market cap and key statistics

BioMarin Pharmaceutical’s market cap is $11.09B and revenue of $3.66B over the last twelve months.

Valuation

Market cap
$11.09B
Forward P/E
8.7
EPS, TTM
−$0.10
Gekko Fair Value
$65.36

Trading

Volume
1.47M
Avg volume, 20 days
2.43M
52-week high
$70.98
52-week low
$49.26
Shares outstanding
193.7M

Financials

Revenue, TTM
$3.66B
Profit margin
-0.5%
Return on equity
-0.3%
Quarterly earnings growth, YoY
−81.3%

Risk and income

Beta
0.23
Typical daily move
±3.4%
Typical 20-day move
±5.3%

BioMarin Pharmaceutical peers

BioMarin Pharmaceutical’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

BioMarin Pharmaceutical stock FAQ

What is BioMarin Pharmaceutical’s market cap?

BioMarin Pharmaceutical’s market cap is $11.09B at the Nov 13, 2026 close of $57.23, with 193.7M shares outstanding.

What is the BioMarin Pharmaceutical stock forecast?

The consensus analyst 12-month price target for BioMarin Pharmaceutical is $90.78, +58.6% from the last close. Of the 23 firms that rated the stock in the last 90 days, 17 rate it a buy, 6 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is BioMarin Pharmaceutical stock overvalued or undervalued?

On Gekko’s estimate BioMarin Pharmaceutical is undervalued: the Nov 13, 2026 close of $57.23 is 12.4% below Gekko Fair Value of $65.36. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does BioMarin Pharmaceutical report earnings next?

BioMarin Pharmaceutical is expected to report on Feb 22, 2027, after the market closes (99 days away). Analysts expect earnings of $0.82 per share on revenue of $1.09B. BioMarin Pharmaceutical beat the earnings estimate in 6 of its last 8 reports, moving 4% on average across the report.

What is BioMarin Pharmaceutical’s 52-week high and low?

BioMarin Pharmaceutical’s 52-week high is $70.98 and its 52-week low is $49.26; it closed at $57.23 on Nov 13, 2026, +3.5% over the past year. Over the last five years the shares peaked at $117.77 on Jan 27, 2023.

Is BioMarin Pharmaceutical stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (fair value, smart money, earnings risk and seasonality), 2 as mixed (trend and gekkoindex). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in BioMarin Pharmaceutical?

Gekko flagged 1 unusual options signal in BioMarin Pharmaceutical over the last 30 days, with $339K of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Oct 21, 2026 with $339K in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See BioMarin Pharmaceutical the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.